



Ref: FOIA Reference 2023/24-152

Date: 3rd July 2023

Email foi@uhn.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 8th June 2023 requesting information under the Freedom of Information Act (2000) regarding migraine.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 How many patients have been treated with the following drugs in the past 4 months?

- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepiti) - any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Rimegepant (Vydura) - any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

A1 See below:

- Erenumab (Aimovig) - any disease - 154
- Eptinezumab (Vyepiti) - any disease -0
- Fremanezumab (Ajovy) - any disease -226
- Galcanezumab (Emgality) - any disease -0
- Rimegepant (Vydura) - any disease - 0
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY - 0

Q2 How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs?

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)

Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

A2 See below: In the last 4 months, note: The numbers of patients on these products does not stay static and does change considerably as patients may try different products before they find one that suits them.

We are able to offer Galcaneumab but it would appear we haven't had any patients on this product (again in the last four months) and that could be because this treatment has a very strict criteria and if you fail to respond you cannot go on to try any other headache drugs, so this maybe also why patients aren't opting for this product and are having results from others we offer.

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Erenumab	108	8
Eptinezumab		
Fremanezumab	58	5
Galcanezumab		
Rimegepant		
Botulinum Toxin	108	

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



Rachel Montinaro
Data Security and Protection Manager - Records